Sermorelin
low riskAlso: GHRH 1-29 · GRF 1-29
Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) approved for pediatric growth hormone deficiency. It stimulates pituitary GH release through the body's own feedback mechanisms, making it a physiologically regulated alternative to exogenous HGH.
Reported Benefits
GH Secretion Stimulation
Well-established stimulation of pulsatile GH release from the pituitary in GH-deficient children.
Adult Body Composition
Adult studies show improvements in lean body mass and fat distribution with sermorelin use.
Sleep Quality
Some data suggests improved deep sleep stages correlating with nocturnal GH pulses.
Mechanism of Action
Sermorelin is a 29-amino-acid fragment of endogenous GHRH (which contains 44 amino acids) that retains full biological activity. It binds to GHRH receptors on pituitary somatotrophs, triggering pulsatile GH release. Because it works through the hypothalamic-pituitary axis, GH release remains subject to normal feedback regulation — distinguishing it from direct GH administration.
Key Clinical Studies
Prakash A, Goa KL (1999)
review · Review of clinical trials
Effective at promoting growth in GH-deficient children comparable to GH therapy
Overview
Sermorelin is the oldest GHRH analog in clinical use, approved in 1997 for pediatric growth hormone deficiency. It represents a more physiological approach to GH optimization than direct recombinant human GH (rhGH) administration because it preserves the pulsatile, feedback-regulated nature of GH secretion.
Pediatric vs. Adult Use
The FDA indication covers pediatric GH deficiency diagnosis and treatment. In adults, sermorelin is widely compounded for anti-aging and body composition protocols, though this use is off-label and lacks the level of evidence behind pediatric applications.
Regulatory Trajectory
Sermorelin’s FDA approval covers specific branded products. Compounded sermorelin for adult anti-aging use exists in a regulatory gray area — technically permissible under 503A provisions but subject to evolving FDA scrutiny of GHRH-class peptides.
Comparison to CJC-1295
Sermorelin’s shorter half-life (less than 12 minutes) makes it more physiologically similar to endogenous GHRH. CJC-1295 extends this half-life substantially, which has both advantages (less frequent dosing) and theoretical concerns regarding feedback dysregulation.
Regulatory Status
FDA ApprovedFDA-approved for pediatric GH deficiency; compounded for adult anti-aging use under 503A
Safety Profile
Side Effects
- •Injection site reactions
- •Flushing
- •Headache
- •Dizziness
- •Water retention
Contraindications
- •Pregnancy
- •Active malignancy
- •Hypothyroidism (untreated)
Drug Interactions
- •Glucocorticoids (antagonize GH response)
- •Thyroid hormones (synergistic)
- •Insulin (monitor glucose)
Primary Uses
Related Peptides
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe Sermorelin?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →